Sunday, February 8, 2026
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Breaking News

Avnets Q3 2024 Revenue Falls Below Analyst Consensus

Elaine Mendonca by Elaine Mendonca
January 31, 2024
in Breaking News
0
Technology Robotics Stock Market Today
0
SHARES
12
VIEWS
Share on FacebookShare on Twitter

As of January 31, 2024, Avnet anticipates generating a revenue between $5.55 billion and $5.85 billion in the third quarter of 2024. This projection falls short of the analyst consensus, which stands at $5.94 billion. Moreover, the company predicts that its diluted earnings per share (EPS) for Q3 will range from $1.05 to $1.15, whereas the estimated EPS is $1.34.

Comparatively, in the same period of the previous year, Avnet disclosed third quarter sales amounting to $6.5 billion and a diluted EPS of $2.03, surpassing their initial forecast. Notably, the company experienced a modest 0.3% increase in revenue for the quarter, reaching $6.51 billion, compared to $6.49 billion in the prior year.

AVT Stock Performance: A Mix of Positive and Negative Indicators on January 31, 2024

On January 31, 2024, AVT stock showcased a mix of positive and negative indicators in its performance. AVT was trading near the top of its 52-week range and above its 200-day simple moving average, indicating positive price momentum. However, the price change on that day presented a slight decline. The stock had increased by $0.27 since the market last closed, representing a rise of 0.57%. However, the stock had dropped $1.87 in pre-market trading. It is important to consider the overall market conditions and news developments throughout the trading day to gain a comprehensive understanding of AVT’s performance.

AVT Stock Shows Promising Performances with Positive Growth in Total Revenue, Net Income, and EPS in 2024

On January 31, 2024, AVT stock showed promising performances, with positive growth in total revenue, net income, and earnings per share (EPS).

AVT’s total revenue for the past year was $26.54 billion, showing a 9.16% increase compared to the previous year. However, in the first quarter of 2024, the total revenue decreased by 3.34% to $6.33 billion.

In terms of net income, AVT reported a net income of $770.83 million for the past year, indicating an 11.33% increase compared to the previous year. In the first quarter of 2024, the net income rose even further to $209.27 million, showing a significant increase of 34.79% since the last quarter.

AVT’s earnings per share (EPS) also experienced positive growth. The EPS for the past year was $8.26, representing a 19.02% increase compared to the previous year. In the first quarter of 2024, the EPS rose to $2.25, showing a substantial increase of 33.99% since the last quarter.

Overall, AVT stock exhibited impressive performances on January 31, 2024. The company’s total revenue, net income, and earnings per share all showed positive growth compared to the previous year and the last quarter. These figures suggest that AVT is on a steady growth trajectory, which may attract investors and contribute to the company’s long-term success.

Tags: AVT
Elaine Mendonca

Elaine Mendonca

Related Posts

NFT projects
Breaking News

The Impact of TikToks Fate on USChina Relations and American Tech Giants

March 16, 2024
Businesses finance
Breaking News

Blackstone Strategic Credit 2027 Term Fund BGB Announces Monthly Dividend of 93 Cents per Share

March 15, 2024
Healthcare-sector
Breaking News

Analyzing Short Interest in Molina Healthcare Inc MOH

March 15, 2024
Next Post

Major Milestone Achieved in NORSE EIGHT Clinical Trial Investigating ONS5010 as a Potential Treatment for Neovascular AgeRelated Macular Degeneration

Finance_ Stock Charts (2)

Analyst Raises Price Target and Expresses Optimism for Axos Financials Future Growth

Stryker Introduces Groundbreaking Footprint Feature in Prophecy Surgical Planning System

Recommended

UBS Stock

UBS Share Buyback Fails to Impress Amid Regulatory Fears

3 months ago
IBM Stock

IBM’s UFC Partnership Showcases AI Capabilities in Live Sports

3 months ago
ImmunityBio Stock

ImmunityBio Shares Gain Momentum on Strong Revenue and Regulatory Progress

6 days ago
BioNTech Stock

BioNTech’s Billion-Euro Forecast Shift Stuns Market

3 months ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Newsletter
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple ASML BioNTech Bitcoin Broadcom Coca-Cola Coinbase D-Wave Quantum Eli Lilly Fiserv IBM Intel Kraft Heinz Marvell Technology META Micron Microsoft MP Materials MSCI World ETF Newmont Mining NIO Novo Nordisk Nvidia Ocugen Opendoor Oracle Palantir PayPal Plug Power QuantumScape Robinhood Rocket Lab USA Strategy Super Micro Computer Synopsys Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics
No Result
View All Result

Highlights

Design Therapeutics Approaches Key Clinical Milestones with Ample Funding

Sanofi Completes Vigil Neuroscience Acquisition, Eyes Alzheimer’s Therapy

Repay Holdings: Annual Report to Test Strategic Refinancing Success

Amazon’s $200 Billion Penalty, The Bad News Rally, and A Cloud Divorce

Graftech Shares Plunge on Bleak Quarterly Results

Potbelly Accelerates Northeast Growth with New Jersey Franchise Push

Trending

Rock Tech Lithium Stock
Analysis

Rock Tech Lithium: Investors Await the Final Go-Ahead

by Jackson Burston
February 8, 2026
0

Investors in Rock Tech Lithium are in a holding pattern, with all eyes fixed on a pending...

Puma Biotechnology Stock

Puma Biotechnology Sets Date for Full-Year Financial Disclosure

February 8, 2026
Quanterix Stock

Quanterix Seeks FDA Clearance for Groundbreaking Alzheimer’s Blood Test

February 8, 2026
Design Therapeutics Stock

Design Therapeutics Approaches Key Clinical Milestones with Ample Funding

February 7, 2026
Vigil Neuroscience Stock

Sanofi Completes Vigil Neuroscience Acquisition, Eyes Alzheimer’s Therapy

February 7, 2026

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • Rock Tech Lithium: Investors Await the Final Go-Ahead
  • Puma Biotechnology Sets Date for Full-Year Financial Disclosure
  • Quanterix Seeks FDA Clearance for Groundbreaking Alzheimer’s Blood Test

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com